Literature DB >> 1335100

Locally recurrent non-small-cell lung cancer after complete surgical resection.

E G Shaw1, J S Brindle, E T Creagan, R L Foote, V F Trastek, S J Buskirk.   

Abstract

Between Jan. 1, 1976, and Dec. 31, 1985, at our institution, 37 patients who had undergone prior complete surgical resection of non-small-cell lung cancer received definitive thoracic radiation therapy (TRT) for locally recurrent disease. Of the 37 recurrences, 33 were in the pulmonary parenchyma or the hilar, mediastinal, or supraclavicular lymph nodes; the other 4 were in the chest wall. The initial stage of disease was I in 43%, II in 35%, and IIIA in 19%, whereas at the time of local recurrence, the stage was I in 8%, II in 11%, IIIA in 57%, IIIB in 22%, and IV in 3% (this patient had multiple pulmonary nodules encompassible within a single TRT field). The locally recurrent lesions were squamous cell carcinoma in 30%, adenocarcinoma or large-cell carcinoma in 46%, mixed types in 5%, and unknown type in 19%. All patients received megavoltage TRT, most often 4,000 cGy in 10 fractions administered in a split-course schedule. In addition, 15 patients received multiagent chemotherapy, usually a combination of cyclophosphamide, doxorubicin hydrochloride, and cisplatin or a regimen that included these drugs. The 2-year and 5-year survivals were 30% and 4%, respectively, and the median duration of survival was 13.7 months. Survival was not improved by the addition of chemotherapy. Approximately half of the patients had radiographic and symptomatic responses after TRT. Of 33 patients assessable for post-TRT patterns of failure, 46% had local failure only, 18% had local plus systemic failure, and 32% had systemic failure only. Two-thirds of the patients died as a direct consequence of progressive chest disease, despite receiving TRT.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1992        PMID: 1335100     DOI: 10.1016/s0025-6196(12)61141-0

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  7 in total

Review 1.  Local recurrence following lung cancer surgery: incidence, risk factors, and outcomes.

Authors:  David Fedor; W Rainey Johnson; Sunil Singhal
Journal:  Surg Oncol       Date:  2013-05-20       Impact factor: 3.279

2.  Prediction and prognostic factors of post-recurrence survival in recurred patients with early-stage NSCLC who underwent complete resection.

Authors:  Pil Jo Choi; Sang Seok Jeong; Sung Sil Yoon
Journal:  J Thorac Dis       Date:  2016-01       Impact factor: 2.895

3.  Genetic amplification of PPME1 in gastric and lung cancer and its potential as a novel therapeutic target.

Authors:  Jing Li; Sufang Han; Ziliang Qian; Xinying Su; Shuqiong Fan; Jiangang Fu; Yuanjie Liu; Xiaolu Yin; Zeren Gao; Jingchuan Zhang; De-Hua Yu; Qunsheng Ji
Journal:  Cancer Biol Ther       Date:  2013-11-19       Impact factor: 4.742

4.  Inhalable magnetic nanoparticles for targeted hyperthermia in lung cancer therapy.

Authors:  Tanmoy Sadhukha; Timothy S Wiedmann; Jayanth Panyam
Journal:  Biomaterials       Date:  2013-04-13       Impact factor: 12.479

5.  Clinical evaluation of stereotactic radiation therapy for recurrent or second primary mediastinal lymph node metastases originating from non-small cell lung cancer.

Authors:  Mao-Bin Meng; Huan-Huan Wang; Nicholas G Zaorsky; Xian-Zhi Zhao; Zhi-Qiang Wu; Bo Jiang; Yong-Chun Song; Hong-Qing Zhuang; Feng-Tong Li; Lu-Jun Zhao; Chang-Li Wang; Kai Li; Ping Wang; Zhi-Yong Yuan
Journal:  Oncotarget       Date:  2015-06-20

6.  High dose involved field radiation therapy as salvage for loco-regional recurrence of non-small cell lung cancer.

Authors:  Sun Hyun Bae; Yong Chan Ahn; Heerim Nam; Hee Chul Park; Hong Ryull Pyo; Young Mog Shim; Jhingook Kim; Kwhanmien Kim; Jin Seok Ahn; Myung-Ju Ahn; Keunchil Park
Journal:  Yonsei Med J       Date:  2012-11-01       Impact factor: 2.759

7.  Salvage radiotherapy for regional lymph node oligo-recurrence after radical surgery of non-small cell lung cancer.

Authors:  Ki Ho Seol; Jeong Eun Lee; Joon Yong Cho; Deok Heon Lee; Yangki Seok; Min Kyu Kang
Journal:  Thorac Cancer       Date:  2017-09-14       Impact factor: 3.500

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.